Stock events for Coherus Oncology, Inc. (CHRS)
Coherus Oncology's stock has been impacted by several events in the past six months. The company reported Q3 2025 financial results with LOQTORZI net revenue of $11.2 million. A public offering of common stock raised approximately $50.1 million. The company announced a significant debt reduction and accelerating commercial launch for LOQTORZI. Senior management presented at the J.P. Morgan Healthcare Conference. The company's share price has been volatile over the past three months.
Demand Seasonality affecting Coherus Oncology, Inc.’s stock price
The provided search results do not contain specific information about demand seasonality for Coherus Oncology, Inc.'s products and services. The nature of oncology treatments and biosimilars typically suggests a more consistent demand driven by patient needs and treatment protocols rather than seasonal fluctuations.
Overview of Coherus Oncology, Inc.’s business
Coherus Oncology, Inc. is a fully integrated commercial-stage oncology company focused on researching, developing, and commercializing immunotherapies to treat cancer in the United States. Key products include LOQTORZI, an approved PD-1 inhibitor; Tagmokitug, an anti-CCR8 antibody in Phase 1b/2a studies; Casdozokitug, an IL-27 antagonist monoclonal antibody; UDENYCA, a biosimilar to Neulasta; YUSIMRY, a biosimilar to Humira; CIMERLI, a Lucentis biosimilar; and CHS-1000, an Anti-ILT4 monoclonal antibody.
CHRS’s Geographic footprint
Coherus Oncology, Inc. is based in Redwood City, California, and primarily operates in the United States. It has licensed the right to commercialize and sell LOQTORZI in Canada to Apotex, Inc. Coherus Oncology owns worldwide rights for its pipeline candidates Casdozokitug and Tagmokitug.
CHRS Corporate Image Assessment
The provided search results do not contain specific information about Coherus Oncology, Inc.'s brand reputation. The company's transformation into an innovative oncology company and its focus on the accelerating commercial launch of LOQTORZI suggest a strategic effort to build a strong presence in the oncology market.
Ownership
The provided search results do not contain specific details about major institutional and individual owners of Coherus Oncology, Inc.
